BON Stock Overview
Manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Boiron SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €23.85 |
| 52 Week High | €36.50 |
| 52 Week Low | €23.45 |
| Beta | 0.42 |
| 1 Month Change | -3.64% |
| 3 Month Change | -9.49% |
| 1 Year Change | -27.29% |
| 3 Year Change | -39.85% |
| 5 Year Change | -27.62% |
| Change since IPO | 59.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| BON | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.7% | -0.5% | -0.5% |
| 1Y | -27.3% | -13.0% | 15.5% |
Return vs Industry: BON underperformed the German Pharmaceuticals industry which returned -13% over the past year.
Return vs Market: BON underperformed the German Market which returned 15.5% over the past year.
Price Volatility
| BON volatility | |
|---|---|
| BON Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: BON has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BON's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1932 | 2,788 | Pascal Houdayer | www.boiron.fr |
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain.
Boiron SA Fundamentals Summary
| BON fundamental statistics | |
|---|---|
| Market cap | €421.04m |
| Earnings (TTM) | €23.69m |
| Revenue (TTM) | €481.71m |
17.8x
P/E Ratio0.9x
P/S RatioIs BON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BON income statement (TTM) | |
|---|---|
| Revenue | €481.71m |
| Cost of Revenue | €130.85m |
| Gross Profit | €350.87m |
| Other Expenses | €327.18m |
| Earnings | €23.69m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.36 |
| Gross Margin | 72.84% |
| Net Profit Margin | 4.92% |
| Debt/Equity Ratio | 1.1% |
How did BON perform over the long term?
See historical performance and comparisonDividends
5.6%
Current Dividend Yield99%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/16 06:28 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Boiron SA is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stéphan Dubosq | Arkeon Finance |
| Guillaume Cuvillier | Gilbert Dupont |
| Stephanie Lefebvre | Gilbert Dupont |